am I the only one who found hepatic fat harder than the injections
The title is the whole question — am I the only one who found hepatic fat harder than the injections — but here is why I am asking. Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing. Nothing containing this…
Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.
Imaging-derived liver fat fraction is a surrogate.
Agreed — and the endpoint definitions are where the actual claim lives.
the weight numbers are secondary to what this is being developed for
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
Has anyone posted an independent purity result for this compound?
MASH endpoints are histological, which is a much harder bar
Which phase and which arm are you quoting?
the hepatic data is what makes this compound different from the others